Metabolic Diseases
Metabolic Diseases
Search
Use of data: "A game changer for our industry"
Data is a game changer for the pharmaceutical industry and will shape our business. Listen to our podcast.
opening-solids-launch-fabrik
Boehringer Ingelheim today opened a tablet factory at Ingelheim in the presence of the State Premier of Rhineland-Palatinate, Malu Dreyer.
Collaboration Boehringer Ingelheim Veeva technology
Boehringer Ingelheim selects Veeva Development Cloud worldwide to bring innovative therapies to patients faster
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Do we keep our promise?
Find out from a father-daughter duo how we live up to our new People Promise.
Data science, agile working, UX design: our evolving IT careers
Meet our IT colleagues working in the fields of user experience, data science and agile development
Top Employer: learning and development with an impact
David has been part of us for over 20 years. What has kept him is part of what makes us a Global Top Employer 2024: our learning and development offerings.
Internal application
Internal applications | FAQ
Our mission in cardiovascular, renal, and metabolic care
Interconnected cardiovascular, renal, and metabolic diseases affect over 1 billion lives globally
More Green Overview
Our pillar MORE GREEN encompasses environmental initiatives that consider many different aspects.
The digital therapeutic solution halving hospitalization rates
Around 750,000 people live with chronic heart failure in Canada. The Medly program empowers patients with heart failure to manage their condition
Online application
Online application | FAQ
Spesolimab prevents GPP flares
Spesolimab prevents generalized pustular psoriasis flares in EFFISAYIL™ 2 trial
CHMP recommends conditional approval for first GPP treatment
CHMP recommends conditional marketing authorization for novel IL-36 receptor monoclonal antibody, spesolimab, as first treatment for generalized pustular psoriasis flares
The GPP Charter
The GPP Charter defines a collaborative approach to identifying common goals for the GPP community
Dan
People with Type 2 diabetes (T2D) have an increased risk of heart disease
Xochimilco
The site in Xochimilco, Mexico, focuses on pharmaceutical production for both Human Pharma and Animal Health.
Positive results Diabetic Macular Ischemia treatment
HORNBILL Phase I/II study shows positive results for potentially first ever Diabetic Macular Ischemia treatment
Liu
Hear Liu share his experience of being diagnosed with type 2 diabetes and heart disease on the same day and the impact this simultaneous diagnosis has had on his life as he knew it.
More Than Scleroderma
A hub of knowledge, advice and support for those whose lives have been touched by scleroderma.
Professor Baumgart
Information for people with type 2 diabetes (T2D) on why it is important to consider their heart and suggested measures that can be taken to reduce the risk of heart disease
Poultry
Poultry
GPP Interview with Professor Barker
An interview with Prof. Barker about generalized pustular psoriasis, its burden on patients and how patient outcomes can be improved
Elke
People with Type 2 diabetes (T2D) have an increased risk of heart disease.